Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 45 of 45 entries
View as:

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Phase: N/A Priority: Normal
NCT ID: NCT01983241 Org: User:
Start: 11/30/13 End: 01/31/27 Due: 01/31/28

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase: N/A Priority: Normal
NCT ID: NCT00220740 Org: User:
Start: 04/30/04 End: 06/30/06 Due: 06/30/07

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05645107 Org: User:
Start: 12/26/22 End: 06/30/26 Due: 06/30/27

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00486837 Org: User:
Start: 12/31/03 End: 06/30/04 Due: 06/30/05

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02282527 Org: User:
Start: 10/31/14 End: 01/31/16 Due: 01/31/17

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04547140 Org: User:
Start: 01/29/21 End: 01/28/22 Due: 01/28/23

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT00301366 Org: User:
Start: 06/30/06 End: 03/31/07 Due: 03/31/08

Alphanate in Immune Tolerance Induction Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03095287 Org: User:
Start: 01/03/18 End: 09/18/20 Due: 09/18/21

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Phase: N/A Priority: Normal
NCT ID: NCT02037555 Org: User:
Start: 06/26/14 End: 01/25/18 Due: 01/25/19

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

Phase: N/A Priority: Normal
NCT ID: NCT00295061 Org: User:
Start: 05/31/06 End: 02/28/07 Due: 02/28/08

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT01222117 Org: User:
Start: 12/31/10 End: 01/31/16 Due: 01/31/17

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04480424 Org: User:
Start: 09/17/20 End: 10/25/21 Due: 10/25/22

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT02093221 Org: User:
Start: 03/31/14 End: 06/30/17 Due: 06/30/18

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

Phase: N/A Priority: Normal
NCT ID: NCT00437671 Org: User:
Start: 03/31/07 End: 09/30/07 Due: 09/30/08

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT00220805 Org: User:
Start: 01/31/04 End: 05/31/05 Due: 05/31/06

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)

Phase: N/A Priority: Normal
NCT ID: NCT03351933 Org: User:
Start: 10/31/17 End: 07/19/18 Due: 07/19/19

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02796937 Org: User:
Start: 07/31/16 End: 02/28/29 Due: 02/28/30

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT04561115 Org: User:
Start: 09/02/20 End: 03/28/22 Due: 03/28/23

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00220779 Org: User:
Start: 12/31/02 End: 02/28/05 Due: 02/28/06

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT04722887 Org: User:
Start: 08/13/21 End: 07/17/25 Due: 07/17/26